PURPOSE: To investigate the levels of angiopoietin-2 (Ang2)and vascular endot helial growth factor (VEGF) in the vitreous fluids of patients with proliferativ e diabetic retinopathy (PDR)and to ascertain their involve...PURPOSE: To investigate the levels of angiopoietin-2 (Ang2)and vascular endot helial growth factor (VEGF) in the vitreous fluids of patients with proliferativ e diabetic retinopathy (PDR)and to ascertain their involvement, if any, in angio genesis of PDR. .DESIGN: Retrospective case-control study. METHODS: Forty-one eyes of 41 patients with proliferative diabetic retinopathy and 18 eyes of 18 pa tients with nondiabetic ocular diseases (control group). Nondiabetic control eye s included 11 with idiopathic macular hole and 7 with idiopathic epiretinal memb rane. Vitreous fluid samples were obtained at vitrectomy, and the levels of Ang2 and VEGF were measured by enzyme-linked immunosorbent assay. RESULTS: Vitreous level (mean ±SD) of Ang2 was significantly higher in patients with PDR (1,753 ±3,213 pg/ml) than in control patients (112 ±.113 pg/ml) (P< .0001). The vitre ous concentration of VEGF was also significantly higher in patients with PDR (81 2 ±1,108 pg/ml) than in control patients (1.7 ±4.4 pg/ml) (P< .0001). Both Ang 2 and VEGF levels in eyes with active PDR were significantly higher than in thos e with inactive PDR. The vitreous concentration of Ang2 correlated significantly with that of VEGF in eyes with proliferative diabetic retinopathy ([correlation coefficient] r=0.497, P=.001). CONCLUSIONS: These data demonstrate an increase of Ang2 in the vitreous fluid of patients with PDR and suggest an association of Ang2 and VEGF with angiogenic activity in PDR.展开更多
文摘PURPOSE: To investigate the levels of angiopoietin-2 (Ang2)and vascular endot helial growth factor (VEGF) in the vitreous fluids of patients with proliferativ e diabetic retinopathy (PDR)and to ascertain their involvement, if any, in angio genesis of PDR. .DESIGN: Retrospective case-control study. METHODS: Forty-one eyes of 41 patients with proliferative diabetic retinopathy and 18 eyes of 18 pa tients with nondiabetic ocular diseases (control group). Nondiabetic control eye s included 11 with idiopathic macular hole and 7 with idiopathic epiretinal memb rane. Vitreous fluid samples were obtained at vitrectomy, and the levels of Ang2 and VEGF were measured by enzyme-linked immunosorbent assay. RESULTS: Vitreous level (mean ±SD) of Ang2 was significantly higher in patients with PDR (1,753 ±3,213 pg/ml) than in control patients (112 ±.113 pg/ml) (P< .0001). The vitre ous concentration of VEGF was also significantly higher in patients with PDR (81 2 ±1,108 pg/ml) than in control patients (1.7 ±4.4 pg/ml) (P< .0001). Both Ang 2 and VEGF levels in eyes with active PDR were significantly higher than in thos e with inactive PDR. The vitreous concentration of Ang2 correlated significantly with that of VEGF in eyes with proliferative diabetic retinopathy ([correlation coefficient] r=0.497, P=.001). CONCLUSIONS: These data demonstrate an increase of Ang2 in the vitreous fluid of patients with PDR and suggest an association of Ang2 and VEGF with angiogenic activity in PDR.
